Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
Primary Purpose
Prader Willi Syndrome
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Syntocinon®/- Spray
Physiological serum (Sodium chloride)
Sponsored by
About this trial
This is an interventional treatment trial for Prader Willi Syndrome focused on measuring Prader Willi syndrome, adults, social behaviour, stress, anxiety, psychological tests
Eligibility Criteria
Inclusion Criteria:
- PWS genetically confirmed,
- Age 18-year-old superior,
- Negative pregnancy test.
Exclusion Criteria:
- Severe psychiatric troubles
- Problem administration staff,
- Saving of justice,
- Abnormalities of the heart rhythm,
- Hepatic or renal insufficiency,
- Pregnancy,
- Oxytocin hypersensibility,
- Treatment causing rhythm disorders.
Sites / Locations
- Hôpital marin d'Hendaye
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Oxytocin
Physiological serum
Arm Description
Outcomes
Primary Outcome Measures
Result scores at Psychological tests : "Reading the mind in the eyes" (RMET), Tests for evaluation of the "theory of mind" : Sally and Ann, Cartoons,"L'esprit des autres", "Social Attribution Task" (SAT).
Secondary Outcome Measures
Result scores at daily stress, anxiety and eating behavior tests
Full Information
NCT ID
NCT01038570
First Posted
November 16, 2009
Last Updated
May 10, 2017
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT01038570
Brief Title
Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
Official Title
Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The role of oxytocin (OT) is already known in the regulation of satiety but some clinical studies demonstrated that OT participates also in the regulation of social behavior by its implication on a better comprehension of emotion which plays a role on theory of mind and empathy. By the way, these 2 behaviors are deviants for patients with Prader-Willi Syndrome (PWS). Actually, no study was led on the effect of OT on PWS patients but Swaab and al in 1995 showed a significant reduction in number and in volume of neurons expressing OT in the paraventricular nucleus of PWS patients. Recent data were obtained studying OT in patients with autism which showed a link between the deregulation of OT and the autistic pathology. Clinical and imaging studies obtained with PWS and autistic populations make us believe that some mechanisms are common between these two pathologies.
The objectives of this project are:
to look for an influence on the understanding of the social codes of the PWS patients,
to look for an influence on the behavior of stress and anxiety and on the regulation of eating habits when patients receive a nasal pulverizing of OT.
Detailed Description
Recent clinical studies showed that the oxytocin (OT), next to its long-time known actions (lactation, satiety), participates in the regulation of the social behavior. Swaab and al in 1995 showed a significant reduction in number and in volume of neurons expressing OT in the paraventricular nucleus of PWS patients. Recent data suggest a link between OT and the autistic pathology: the existence of a lower plasmatic rate on OT and the association with a polymorphism of the OT's receptor for autistics patients. Because OT has a role on the pro-social behavior and on the nervous control of the stress, the hypothesis on which a deficit in OT would play a role in the abnormalities of the social behavior was advanced. Moreover, certain features of the autistic spectrum disorder can be found in PWS patients. Moreover, a recent study has shown that OT administered by intra-nasal spray reduces psychosocial stress and increases the confidence in each other in healthy volunteers. The PWS is a genetic pathology and some clinical features are very similar to the autistic pathology. The PWS is the most common cause of syndromic autism. Data from the literature and a collaborative study conducted between our team and the Prof. B. Rogé's team suggests that these two pathologies share common pathophysiological mechanisms. To our knowledge, no study with the OT was conducted in people with PWS. We want to conduct a pilot study in adult patients with PWS. Given the severity of this disease, related to socialization disorders, significant anxiety and overeating, and with no effective therapy, this justifies the pilot study. Moreover, side effects of OT are almost nonexistent when used by intra-nasal.
Objectives: The objectives of this project are to investigate whether the administration by intra-nasal spray of OT plays a role on the understanding of social codes of PWS adult patients. We also analyze its effect on the level of stress, anxiety and eating behavior.
Methodology: This study is a double blind control study. We will include 24 PWS patients, aged over 18 years recruited at the Hendaye Marine Hospital (associated with the PWS reference center whose coordination is in Toulouse). The hospital routinely receives PWS adults for a 4 weeks stay which gives optimal conditions for the establishment of this study. Patients are separated into 2 groups matched one by one on the sex and IQ. One group receives the OT, the other a placebo. Forty five minutes after inhalation, all of the patients are evaluated on their social comprehension thanks to psychometric tests. Furthermore, an analysis based on observation sheets allows us to score daily stress, anxiety and eating behavior. These sheets serve for the comparison between 2 days before and 2 days after the nasal spray on the above described scoring components.
Results: Differences between the two groups will be statistically analyzed by non parametric statistical tests such as Mann-Whitney's test.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prader Willi Syndrome
Keywords
Prader Willi syndrome, adults, social behaviour, stress, anxiety, psychological tests
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oxytocin
Arm Type
Experimental
Arm Title
Physiological serum
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Syntocinon®/- Spray
Intervention Description
3 sprays corresponding to 24 IU in each nostril
Intervention Type
Drug
Intervention Name(s)
Physiological serum (Sodium chloride)
Intervention Description
Sodium chloride 0.9 % (0.3 ml) in each nostril
Primary Outcome Measure Information:
Title
Result scores at Psychological tests : "Reading the mind in the eyes" (RMET), Tests for evaluation of the "theory of mind" : Sally and Ann, Cartoons,"L'esprit des autres", "Social Attribution Task" (SAT).
Time Frame
fourth day
Secondary Outcome Measure Information:
Title
Result scores at daily stress, anxiety and eating behavior tests
Time Frame
Five days (first day to fifth day)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PWS genetically confirmed,
Age 18-year-old superior,
Negative pregnancy test.
Exclusion Criteria:
Severe psychiatric troubles
Problem administration staff,
Saving of justice,
Abnormalities of the heart rhythm,
Hepatic or renal insufficiency,
Pregnancy,
Oxytocin hypersensibility,
Treatment causing rhythm disorders.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maïthé TAUBER, MD
Organizational Affiliation
Centre de référence du syndrome de Prader-Willi - Equipe d'Endocrinologie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital marin d'Hendaye
City
Hendaye
State/Province
Pyrénées-Atlantiques
ZIP/Postal Code
64704
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21702900
Citation
Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Roge B, Laurier V, Ehlinger V, Arnaud C, Molinas C, Thuilleaux D. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011 Jun 24;6:47. doi: 10.1186/1750-1172-6-47.
Results Reference
result
Learn more about this trial
Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
We'll reach out to this number within 24 hrs